Cardiovascular Clinical Features and Therapies in the Progression and Outcome of Patients With SARS-CoV-2 Pneumonia

What this Trial Is About

This research aims to identify factors that predict the progression of cardiovascular disease and death in patients hospitalized with COVID-19. It involves patients who tested positive for the SARS-CoV-2 virus and were admitted to a hospital in northern Italy due to worsening COVID-19 symptoms. The study does not introduce new treatments but observes outcomes based on current clinical practices. The study includes both past and ongoing data collection of patients treated according to standard clinical care. Information gathered includes medical history with attention to heart and lung risk factors, physical exam details, lab and imaging test results, and treatments given before and during hospitalization. Researchers analyze these data to uncover links between patient characteristics and disease progression. Participants are followed to measure mortality at 30 days, 6 months, and 1 year after hospitalization. The study carefully tracks patient outcomes and uses statistical methods to understand which factors affect health over time. Participation involves no additional treatments beyond regular care, and data collection continues as part of routine medical follow-up until the study ends.

CardioVascular Disease Progression and Prognosis in COVID-19